WO2010092185A3 - Inhibiteurs de l'intération scramblase/cd4 pour le traitement d'infections à lentivirus - Google Patents

Inhibiteurs de l'intération scramblase/cd4 pour le traitement d'infections à lentivirus Download PDF

Info

Publication number
WO2010092185A3
WO2010092185A3 PCT/EP2010/051927 EP2010051927W WO2010092185A3 WO 2010092185 A3 WO2010092185 A3 WO 2010092185A3 EP 2010051927 W EP2010051927 W EP 2010051927W WO 2010092185 A3 WO2010092185 A3 WO 2010092185A3
Authority
WO
WIPO (PCT)
Prior art keywords
scramblase
treatment
interaction inhibitors
lentivirus infections
lentivirus
Prior art date
Application number
PCT/EP2010/051927
Other languages
English (en)
Other versions
WO2010092185A2 (fr
Inventor
Serge Benichou
Stéphane BASMACIOGULLARI
Bénédicte PY
Jérôme BOUCHET
Ricardo Madrid
Benoit Deprez
Florence Leroux
Original Assignee
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Centre National De La Recherche Scientifique (C.N.R.S)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Sante Et De La Recherche Medicale (Inserm), Centre National De La Recherche Scientifique (C.N.R.S) filed Critical Institut National De La Sante Et De La Recherche Medicale (Inserm)
Publication of WO2010092185A2 publication Critical patent/WO2010092185A2/fr
Publication of WO2010092185A3 publication Critical patent/WO2010092185A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention est relative à l'obtention de molécules capables d'inhiber l'interaction du domaine cytoplasmique de CD4 avec une scramblase, et à l'utilisation de ces molécules pour inhiber l'infection par un VIH ou un lentivirus apparenté.
PCT/EP2010/051927 2009-02-16 2010-02-16 Inhibiteurs de l'intération scramblase/cd4 pour le traitement d'infections à lentivirus WO2010092185A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290110 2009-02-16
EP09290110.7 2009-02-16

Publications (2)

Publication Number Publication Date
WO2010092185A2 WO2010092185A2 (fr) 2010-08-19
WO2010092185A3 true WO2010092185A3 (fr) 2011-01-20

Family

ID=40810510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/051927 WO2010092185A2 (fr) 2009-02-16 2010-02-16 Inhibiteurs de l'intération scramblase/cd4 pour le traitement d'infections à lentivirus

Country Status (1)

Country Link
WO (1) WO2010092185A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018832A1 (fr) * 1993-02-26 1994-09-01 Dana-Farber Cancer Institute, Inc. Modulation a mediation cd4 de kinases lipidiques
WO2001016182A2 (fr) * 1999-08-27 2001-03-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polypeptides de liaison a la glycoproteine gp120 du virus de l'immunodeficience humaine (vih), acides nucleiques, anticorps et compositions associes, et methodes d'utilisation
WO2006098724A1 (fr) * 2005-03-11 2006-09-21 The Regents Of The University Of California Procedes destines au traitement du vih en inhibant la modulation decroissante du cd4
WO2007135684A2 (fr) * 2006-05-22 2007-11-29 Hadasit Medical Research Services & Development Limited Procédé de traitement d'auto-immunité anti-cd4
WO2008037026A1 (fr) * 2006-09-28 2008-04-03 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Procédé de diagnostic et coffret pour ledit procédé

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869925B1 (en) 1992-09-09 2005-03-22 Amgen Inc. Inhibition of retrovirus infection
US6017880A (en) 1994-03-09 2000-01-25 Amgen Inc. Inhibition of retrovirus infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018832A1 (fr) * 1993-02-26 1994-09-01 Dana-Farber Cancer Institute, Inc. Modulation a mediation cd4 de kinases lipidiques
WO2001016182A2 (fr) * 1999-08-27 2001-03-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polypeptides de liaison a la glycoproteine gp120 du virus de l'immunodeficience humaine (vih), acides nucleiques, anticorps et compositions associes, et methodes d'utilisation
WO2006098724A1 (fr) * 2005-03-11 2006-09-21 The Regents Of The University Of California Procedes destines au traitement du vih en inhibant la modulation decroissante du cd4
WO2007135684A2 (fr) * 2006-05-22 2007-11-29 Hadasit Medical Research Services & Development Limited Procédé de traitement d'auto-immunité anti-cd4
WO2008037026A1 (fr) * 2006-09-28 2008-04-03 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Procédé de diagnostic et coffret pour ledit procédé

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TSENG<A> C-C ET AL: "Identification of a novel secretory leukocyte protease inhibitor-binding protein involved in membrane phospholipid movement", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 475, no. 3, 23 June 2000 (2000-06-23), pages 232 - 236, XP004337268, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
WO2010092185A2 (fr) 2010-08-19

Similar Documents

Publication Publication Date Title
EA201101620A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
AU2014230129A8 (en) Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
TN2011000673A1 (en) Bace inhibitors
EA201200559A1 (ru) Способы назначения терапии пирфенидоном
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
MX2013006113A (es) Compuestos biciclico.
UA105556C2 (uk) Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
WO2013070615A8 (fr) Polythérapies utilisant des molécules de liaison anti-psl et pcrv de pseudomonas
WO2012116010A3 (fr) Inhibiteurs de la tolérance aux antibiotiques
WO2012106534A3 (fr) Inhibiteurs de l&#39;intégrase du vih
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
WO2011071904A3 (fr) Inhibition des infections bactériennes et de la formation de biofilms
WO2012170807A3 (fr) Molécules de liaison anti-psl de pseudomonas et leurs utilisations
CA2798214C (fr) Vaccin contre une infection a virus herpes beta et utilisation correspondante
WO2011143772A9 (fr) Inhibiteurs de la réplication du vih
EP2555798A4 (fr) Procédés et compositions pour l&#39;inhibition de la transmission du vih
WO2010053573A3 (fr) Criblage d&#39;inhibiteurs de filovirus et leurs utilisations
WO2012106702A3 (fr) Traitement de la leucémie
WO2013060744A3 (fr) Composés présentant une activité d&#39;inhibition d&#39;ethr, utilisation desdits composés en tant que médicaments, composition pharmaceutique et produit contenant lesdits composés
WO2010059639A3 (fr) Inhibiteurs à base d&#39;hydroxyadamantyle de dipeptidylpeptidase iv
WO2008048689A3 (fr) Méthodes de traitement d&#39;une dystrophie musculaire associée à une carence en dysferline
WO2010092185A3 (fr) Inhibiteurs de l&#39;intération scramblase/cd4 pour le traitement d&#39;infections à lentivirus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10705580

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10705580

Country of ref document: EP

Kind code of ref document: A2